History of Vaccines Blog
New Shingles Vaccine Approval and Recommendations
Philadelphia Study Examines Varicella and Herpes Zoster
By Thomas Fekete, MD, FCPP, Section Chief, Infectious Diseases; Professor, Medicine; Associate Professor, Microbiology and Immunology; School of Medicine, Temple University
Phase 3 Trial of Recombinant Shingles Vaccine Shows Promise in Older Adults
The herpes zoster vaccine commercially available in the United States (Zostavax, Merck, generic zoster vaccine live) is 51% effective at preventing shingles in adults ages 60 and older, but it is less effective for older adults. For those over age 70, it is only 38% effective at preventing disease.
From ID Week: Adult Immunization Barriers and Promoters
How is the immune system similar to your marathon time? As we age, our immune response decreases at the same slope that our marathon race times increase. Presenters described this and some of the other problems of immunizing adults in the Symposium on Adult Immunizations, an early session at the Infectious Diseases Society 2014 conference at the Philadelphia Convention Center.